(Q38618178)

4 September 2017

title

Therapeutic innovations in inflammatory bowel diseases (English)

1 reference

inflammatory bowel diseases

4 September 2017

main subject

0 references

author

Séverine Vermeire

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

W Vanhove

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

K Nys

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

28 October 2015

1 reference

Clinical Pharmacology & Therapeutics

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

49-58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

5 June 2020

cites work

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials.

21 January 2018

1 reference

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

21 January 2018

1 reference

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases

21 January 2018

1 reference

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

21 January 2018

1 reference

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease

21 January 2018

1 reference

Iron, anaemia, and inflammatory bowel diseases.

21 January 2018

1 reference

Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease

21 January 2018

1 reference

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

21 January 2018

1 reference

Introducing vedolizumab to clinical practice: who, when, and how?

21 January 2018

1 reference

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

21 January 2018

1 reference

Smad7 in TGF-beta-mediated negative regulation of gut inflammation

21 January 2018

1 reference

TGF-beta1 and Smad7 in the regulation of IBD.

21 January 2018

1 reference

Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease

21 January 2018

1 reference

Oral SMAD7 antisense drug for Crohn's disease.

21 January 2018

1 reference

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

21 January 2018

1 reference

An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis

21 January 2018

1 reference

Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys

21 January 2018

1 reference

Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.

21 January 2018

1 reference

Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease.

21 January 2018

1 reference

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study

21 January 2018

1 reference

A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy

21 January 2018

1 reference

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

21 January 2018

1 reference

Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.

21 January 2018

1 reference

Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial

21 January 2018

1 reference

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease

21 January 2018

1 reference

Unravelling the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

Colony stimulating factor-1 dependence of paneth cell development in the mouse small intestine.

21 January 2018

1 reference

Reduced Paneth cell alpha-defensins in ileal Crohn's disease

21 January 2018

1 reference

Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics

21 January 2018

1 reference

Intestinal barrier function: molecular regulation and disease pathogenesis

21 January 2018

1 reference

Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk

21 January 2018

1 reference

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

21 January 2018

1 reference

The unfolded protein response and its role in intestinal homeostasis and inflammation.

21 January 2018

1 reference

Autophagy: renovation of cells and tissues

21 January 2018

1 reference

Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease.

21 January 2018

1 reference

Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress.

21 January 2018

1 reference

The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice

21 January 2018

1 reference

Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death.

21 January 2018

1 reference

Autophagy: a new target or an old strategy for the treatment of Crohn's disease?

21 January 2018

1 reference

Use of sirolimus (rapamycin) to treat refractory Crohn's disease

21 January 2018

1 reference

The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.

21 January 2018

1 reference

Enterotypes of the human gut microbiome

21 January 2018

1 reference

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.

21 January 2018

1 reference

CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease

21 January 2018

1 reference

A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis

21 January 2018

1 reference

The treatment-naive microbiome in new-onset Crohn's disease

21 January 2018

1 reference

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

21 January 2018

1 reference

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

Gene expression signature for recurrence in stage III colorectal cancers.

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

21 January 2018

1 reference

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment

21 January 2018

1 reference

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

21 January 2018

1 reference

Current directions in IBD therapy: what goals are feasible with biological modifiers?

21 January 2018

1 reference

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

21 January 2018

1 reference

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

21 January 2018

1 reference

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

7 January 2021

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

7 January 2021

Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies

1 reference

7 January 2021

[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]

1 reference

7 January 2021

Expression of vascular adhesion molecules in inflammatory bowel disease

1 reference

7 January 2021

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7

1 reference

7 January 2021

Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis

1 reference

7 January 2021

Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease

1 reference

7 January 2021

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease

1 reference

7 January 2021

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

1 reference

7 January 2021

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease

1 reference

7 January 2021

Stem cells as potential novel therapeutic strategy for inflammatory bowel disease

1 reference

7 January 2021

Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor

1 reference

7 January 2021

Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPT.286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26509246%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference